Angiotensin-converting enzyme inhibition in myocardial infarction--Part 1: Clinical data.
There is an increasing body of clinical trial evidence to support the use of angiotensin-converting enzyme (ACE) inhibitors in the management of patients following myocardial infarction (MI). Enthusiasm for the use of ACE inhibitors in the acute phase of MI had previously been tempered by the adverse results of an early trial. However, exciting new information is available from several large, randomized studies that has not only quelled those initial concerns but also attests to the efficacy of using this class of medication in the first 24 h after an acute MI. A Canadian National Opinion Leader Symposium was held in November 1995 to review the results of the major ACE inhibitor clinical trials and to discuss key issues and controversies surrounding their use in acute MI. The focus of this paper, the first of two parts, is on the results of the major ACE inhibitor clinical trials.
Huckell
V F
VF
Vancouver Hospital, British Columbia. huckell@mindlink.bc.ca
Bernstein
V
V
Cairns
J A
JA
Crowell
R
R
Dagenais
G R
GR
Higginson
L A
LA
Isserow
S
S
Laramée
P
P
Liu
P
P
McCans
J L
JL
Orchard
R C
RC
Prewitt
R
R
Quinn
B P
BP
Samson
M
M
Turazza
F
F
Warnica
J W
JW
Wielgosz
A
A
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D012307:Risk Factors
D000806:Angiotensin-Converting Enzyme Inhibitors